+1.650.627.4531 inquiry@medeortx.com
Contact Us| Find us on:

Senior Management



Karen Smith, President & CEO
Karen Smith, MD, PhD, MBA, LLM


Karen Smith, MD, PhD, MBA, LLM, is President and Chief Executive Officer. Prior to Medeor, Dr. Smith was the CEO of an international organization focused on oncology therapeutics in late stage clinical trials. Prior to that, Dr. Smith was the Chief Medical Officer for Jazz Pharmaceuticals leading the development and approval of Vyxeos and Defitelio. Her breadth of experience covers diverse therapeutic areas including oncology, rare disease, cardiology, dermatology, and neuroscience; as well as a successful record of acquisitions, divestitures, and partnership deals. Dr. Smith has previously served on the boards of Forward Pharma and Sucampo and is currently serving as a Director for Acceleron Pharma, Antares Pharma, and Sangamo Therapeutics.

Dr. Smith holds an MD in Cardiology, PhD in Molecular Oncology, MBA, and a Masters in Law.



Darin J. Weber,Senior VP, Regulatory Affairs & Quality
Darin J. Weber, PhD


Darin J. Weber, PhD is Senior Vice President and Chief Regulatory Officer. Since joining the Company in 2016 he has been responsible for the Regulatory Affairs and Quality Assurance functions. Previously, he was Executive Vice President, Global Regulatory Affairs and Quality Management at Mesoblast LTD from June 2011 to February 2016. Dr. Weber previously was a Senior Consultant for cellular and gene therapies at Biologics Consulting Group, LLC from February 2004 to June 2011. From September 1996 to February 2004 Dr. Weber held positions of increasing responsibility at the FDA’s Center for Biologics Evaluation and Research, including as Chief of Cellular Therapies Branch in the Office of Cellular, Tissues and Gene Therapies, (now known as the Office of Tissues and Advanced Therapies).

Dr. Weber received his BS from The Evergreen State College and his PhD in Biochemistry and Biophysics from Oregon State University.



Michael Zdanowski, VP, Biopharmaceutical Operations
Michael Zdanowski


Michael Zdanowski is Senior Vice President of Biopharmaceutical Operations, responsible for development, manufacturing and quality control. He joined the Medeor team in March 2018. Mr. Zdanowski brings more than 20 years of GMP operations and manufacturing experience. He is experienced in the development and optimization of cell-therapy products in complex regulatory environments. Previously, he served as Vice President of GMP Operations at the New York Stem Cell Foundation, Vice President of Manufacturing at Mesoblast LTD, and Director of Operations of the National Cord Blood Program at the New York Blood Center, where he led the team in the preparation and submission of the first successful BLA for an allogeneic cell therapy product.

Mr. Zdanowski received his BS in Mechanical Engineering and BA in Philosophy from the University of Pennsylvania, and his MBA from Columbia University.



Suzanne Crowley, VP, Clinical Operations
Suzanne Crowley

Vice President, Clinical Operations

Ms. Crowley joined Medeor in March 2019 as the Vice President of Clinical Operations. Prior to Medeor, Ms. Crowley was at Swedish Orphan Biovitrum AB, North America between 2011 and 2019, where she served in several positions of increasing responsibility including Director of Medical Affairs Operations and Associate Director of Strategy. Ms. Crowley did serve as the president of her own consulting company between 2010 and 2014. Ms. Crowley previously worked at Genzyme Transplant and 0ncology between 2003 and 2010, where she was the Director External Research / Director Global Pre-clinical ISS Program Transplant /Oncology. Before joining Genzyme, Ms. Crowley was a Medical Science Liaison for SangStat, between 1999 and 2003.

Ms. Crowley is a nurse practitioner and received her BSN from Syracuse University and her MS-CROM from Drexel University, College of Medicine.



Corrina Chen, VP Corporate Development


Corinna Chen is Vice President of Corporate Development, responsible for corporate and business development as well as new product planning. She has been with Medeor since March 2018. Ms. Chen has business and development experience within a wide range of therapeutic areas including neuroscience, pain, anesthesiology, cardiology, and surgery. Ms. Chen’s record of licensing, acquisition, divestiture, and new-company-formation deals totals over $1B across several products and geographies. She led business development and strategy for the surgery business unit at The Medicines Company, where she focused on growth through worldwide partnerships and commercialization of novel therapies. Her additional experience spans therapeutics, medtech, and diagnostics at companies including Alexza Pharmaceuticals, Incline Therapeutics, and Acelrx Pharmaceuticals.

She holds a BS in Electrical Engineering from Boston University and MBA from Duke University.